The 2-min walk test is sufficient for evaluating walking abilities in sporadic inclusion body myositis

被引:23
作者
Alfano, L. N. [1 ]
Lowes, L. P. [1 ]
Dvorchik, I. [2 ]
Yin, H. [2 ]
Maus, E. G. [1 ]
Flanigan, K. M. [1 ]
Mendell, J. R. [1 ]
机构
[1] Nationwide Childrens Hosp, Res Inst, Ctr Gene Therapy, Columbus, OH 43205 USA
[2] Nationwide Childrens Hosp, Res Inst, Biostat Core, Columbus, OH 43205 USA
关键词
Sporadic inclusion body myositis; Outcome measure; 2-min walk test; 6-min walk test; Function; NATURAL-HISTORY; DISTANCE; THERAPY; DISEASE;
D O I
10.1016/j.nmd.2013.11.012
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Sporadic inclusion body myositis causes progressive functional loss due to declining muscle strength. Although the underlying cause is unknown, clinical trials are underway to improve strength and function. Selection of appropriate outcome measures is critical for the success of these trials. The 6-min walk test has been the de facto standard for assessing function in neuromuscular disease; however, the optimal walking test has not been determined in this disease. In this study, 67 individuals with sporadic inclusion body myositis completed a battery of quantitative strength and functional tests including timed walking tests, patient-reported outcomes, and other tasks. The 2-min and 6-min walk tests are highly correlated to each other (r = 0.97, p < 0.001) and to all lower extremity strength, patient-reported, and functional measures in this population. All subjects completed the 2-min walk test, but 7% of subjects were unable to walk the full 6-min of the 6-min walk test due to fatigue. The 2-min walk test demonstrates similar correlation to all outcomes compared to the 6-min walk test, is less fatiguing and better tolerated. Results suggest that the 2-min walk test is a better alternative to tests of longer duration. Further research is needed to determine longitudinal changes on this outcome. (C) 2013 Elsevier B.V. All rights reserved.
引用
收藏
页码:222 / 226
页数:5
相关论文
共 30 条
[11]   Pathogenesis and therapy of inclusion body myositis [J].
Greenberg, Steven A. .
CURRENT OPINION IN NEUROLOGY, 2012, 25 (05) :630-639
[12]   INCLUSION-BODY MYOSITIS AND MYOPATHIES [J].
GRIGGS, RC ;
ASKANAS, V ;
DIMAURO, S ;
ENGEL, A ;
KARPATI, G ;
MENDELL, JR ;
ROWLAND, LP .
ANNALS OF NEUROLOGY, 1995, 38 (05) :705-713
[13]  
Hilton-Jones D, 2010, NEUROMUSCULAR DISORD, V20, P622, DOI [10.1016/j.nmd.2009.11.003, 10.1016/j.nmd.2010.07.087]
[14]   Inclusion body myositis functional rating scale: A reliable and valid measure of disease severity [J].
Jackson, C. E. ;
Barohn, R. J. ;
Gronseth, G. ;
Pandya, S. ;
Herbelin, L. .
MUSCLE & NERVE, 2008, 37 (04) :473-476
[15]  
Jenkins Sue, 2009, Physiotherapy Theory and Practice, V25, P516, DOI [10.1080/09593980802664711, 10.3109/09593980802664711]
[16]  
Johnson Liam G, 2009, J Clin Neuromuscul Dis, V10, P178, DOI 10.1097/CND.0b013e3181a23c86
[17]  
Karapolat Hale, 2006, Anadolu Kardiyol Derg, V6, P327
[18]   Classification, Diagnosis, and Management of Idiopathic Inflammatory Myopathies [J].
Lazarou, Ilias N. ;
Guerne, Pierre-Andre .
JOURNAL OF RHEUMATOLOGY, 2013, 40 (05) :550-564
[19]   Reliability and clinical significance of mobility and balance assessments in multiple sclerosis [J].
Learmonth, Yvonne C. ;
Paul, Lorna ;
McFadyen, Angus K. ;
Mattison, Paul ;
Miller, Linda .
INTERNATIONAL JOURNAL OF REHABILITATION RESEARCH, 2012, 35 (01) :69-74
[20]   Prognosis and prognostic factors in sporadic inclusion body myositis [J].
Lindberg, C. ;
Oldfors, A. .
ACTA NEUROLOGICA SCANDINAVICA, 2012, 125 (05) :353-358